<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Ferric pyrophosphate citrate: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Ferric pyrophosphate citrate: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Ferric pyrophosphate citrate: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="99860" href="/d/html/99860.html" rel="external">see "Ferric pyrophosphate citrate: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F45497291"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Triferic AVNU [DSC];</li>
<li>Triferic [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F26978883"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Iron Preparations</li></ul></div>
<div class="block doa drugH1Div" id="F27377914"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Triferic ampules (intradialytic formulation) contains 5.44 mg iron (III) per mL. Triferic powder (intradialytic formulation) contains 272 mg iron (III) per packet. Triferic AVNU (IV formulation) contains 1.5 mg iron (III) per mL.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="55344550-05a0-46da-b8b8-56e80a51077d">Iron replacement therapy in hemodialysis-dependent patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Iron replacement therapy in hemodialysis-dependent patients:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> The doses below are considered maintenance doses to replace ongoing iron losses; alternative IV iron products (that can be administered at higher doses) may still be necessary in patients presenting with or developing iron deficiency (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35726771']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35726771'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Intradialytic:</b> After admixture into bicarbonate concentrate dialysate (final concentration 2 micromolar [110 mcg/L]) use at each dialysis session. Therapy may be continued for as long as the patient is receiving maintenance hemodialysis for chronic kidney disease (CKD).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>IV:</b> 6.75 mg with each dialysis session. Therapy may be continued for as long as the patient is receiving maintenance hemodialysis for CKD.</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991951"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doha drugH1Div" id="F50989251"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F27164846"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Frequency not always defined.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Cardiovascular: Procedural hypotension (22%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Peripheral edema (7%), clotted AV fistula (3%), dialysis access hemorrhage (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (9%), fatigue (4%), dizziness</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Pruritus</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Constipation, nausea</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary tract infection (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle spasm (10%), limb pain (7%), back pain (5%), weakness (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Dyspnea (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever (5%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Anaphylaxis, hypersensitivity</p></div>
<div class="block coi drugH1Div" id="F26978800"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F27377902"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hypersensitivity: Serious hypersensitivity reactions, including anaphylactic-type reactions (some fatal) have been reported in patients receiving parenteral iron products. Monitor for signs and symptoms of hypersensitivity (eg, shock, hypotension, loss of consciousness, collapse) during and after hemodialysis.</p></div>
<div class="block foc drugH1Div" id="F45497292"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Packet, Hemodialysis: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Triferic: 272 mg (1 ea [DSC], 100 ea [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Hemodialysis [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Triferic: 27.2 mg/5 mL (5 mL [DSC])</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Triferic AVNU: 6.75 mg/4.5 mL (5 mL [DSC])</p></div>
<div class="block geq drugH1Div" id="F44809988"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F45088622"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pack</b> (Triferic Hemodialysis)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">272 mg (per each): $96.00</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Triferic AVNU Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">6.75MG/4.5ML (per mL): $2.88</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Triferic Hemodialysis)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">27.2 mg/5 mL (per mL): $2.28</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F27377917"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intradialytic:</b> Administer after admixed into bicarbonate concentrate dialysate at each dialysis session.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>IV:</b> Administer as slow continuous infusion over 3 to 4 hours via the pre-dialyzer infusion line, post-dialyzer infusion line, or via a separate connection to the venous blood line at each dialysis session.</p></div>
<div class="block use drugH1Div" id="F26974576"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Iron replacement therapy in hemodialysis-dependent patients:</b> Replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (HDD-CKD)</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Not intended for use in patients receiving peritoneal dialysis; has not been studied in patients receiving home hemodialysis</p></div>
<div class="block cyt drugH1Div" id="F27004216"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F27004213"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Dimercaprol: May enhance the nephrotoxic effect of Iron Preparations.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levonadifloxacin: Iron Preparations may decrease the serum concentration of Levonadifloxacin. <i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F53559902"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">The manufacturer recommends effective contraception during therapy and for at least 2 weeks after treatment is complete in females of reproductive potential.</p></div>
<div class="block pri drugH1Div" id="F27377899"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Adverse events were observed in some animal reproduction studies.</p>
<p style="text-indent:0em;margin-top:2em;">Maternal iron requirements increase during pregnancy. Adequate iron concentrations to the fetus can be maintained regardless of maternal iron status, except in severe cases of anemia (IOM 2001).</p></div>
<div class="block brc drugH1Div" id="F27377901"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Iron is present in breast milk (IOM 2001). It is not known if maternal exposure to ferric pyrophosphate citrate significantly changes breast milk concentrations.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F27377919"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor for hypersensitivity reactions during and after the dialysis session. Determine iron status on predialysis blood samples, as postdialysis serum iron parameters may overestimate serum iron and transferrin saturation. Patients with chronic kidney disease should have anemia indices (including hemoglobin, hematocrit, and iron studies) assessed as clinically indicated in routine care.</p></div>
<div class="block rer drugH1Div" id="F59008039"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Anemia:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Hemoglobin, whole blood:</p>
<p style="text-indent:-2em;margin-left:6em;">Female: 12 to16 g/dL (SI: 120 to 160 g/L) (ABIM 2023).</p>
<p style="text-indent:-2em;margin-left:6em;">Male: 13 to 18 g/dL (SI: 130 to 180 g/L) (ABIM 2023; WHO 2011).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Iron deficiency (ABIM 2023):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Ferritin, serum: <b>Note:</b> Ferritin is an acute phase reactant; levels may be elevated in the presence of inflammation or infection which is independent of iron status (WHO 2020).</p>
<p style="text-indent:-2em;margin-left:6em;">Female: 24 to 307 ng/mL (SI: 53.9 to 689.8 picomole/L).</p>
<p style="text-indent:-2em;margin-left:6em;">Male: 24 to 336 ng/mL (SI: 53.9 to 755 picomole/L).</p>
<p style="text-indent:-2em;margin-left:4em;">Iron, serum: 50 to 150 mcg/dL (SI: 9 to 26.9 micromole/L).</p>
<p style="text-indent:-2em;margin-left:4em;">Total iron binding capacity, serum: 250 to 310 mcg/dL (SI: 44.8 to 55.5 micromole/L).</p>
<p style="text-indent:-2em;margin-left:4em;">Transferrin saturation: 20% to 50%.</p>
<p style="text-indent:-2em;margin-left:4em;">Transferrin, serum: 200 to 400 mg/dL (SI: 24.6 to 49.2 micromole/L).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Chronic kidney disease–associated anemia:</b> To achieve and maintain target hemoglobin for patients with nondialysis-dependent chronic kidney disease, patients with a transferrin saturation (TSAT) ≤30% and a serum ferritin level ≤500 ng/mL (SI: 1,123.5 picomole/L) will often respond to iron supplementation (Gutiérrez 2021; KDIGO 2012).</p></div>
<div class="block pha drugH1Div" id="F27377908"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Iron delivered into the circulation binds to transferrin for transport to erythroid precursor cells to be incorporated into hemoglobin.</p></div>
<div class="block phk drugH1Div" id="F27377910"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 0.765 to 0.859 L</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~1.48 hours</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F58845832"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Sideral</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-ABIM.1">
<a name="ABIM.1"></a>American Board of Internal Medicine (ABIM). Laboratory Test Reference Ranges. <i>Lexi-Drugs</i>. UpToDate Lexidrug. Waltham, MA: UpToDate Inc. https://online.lexi.com. Accessed December 11, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35726771">
<a name="35726771"></a>Fishbane S, Ganz T, Pratt RD. Ferric pyrophosphate citrate for parenteral administration of maintenance iron: structure, mechanism of action, clinical efficacy and safety. <i>Curr Med Res Opin</i>. 2022;38(8):1417-1429. doi:10.1080/03007995.2022.2092373<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-pyrophosphate-citrate-drug-information/abstract-text/35726771/pubmed" id="35726771" target="_blank">35726771</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34514189">
<a name="34514189"></a>Gutiérrez O. Treatment of iron deficiency anemia in CKD and end-stage kidney disease. <i>Kidney Int Rep. </i>2021;6(9):2261-2269. doi:10.1016/j.ekir.2021.05.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/ferric-pyrophosphate-citrate-drug-information/abstract-text/34514189/pubmed" id="34514189" target="_blank">34514189</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  IOM (Institute of Medicine). <i>Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc</i>. Washington, DC: National Academy Press; 2001.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-KDIGO.1">
<a name="KDIGO.1"></a>Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guidelines for anemia in chronic kidney disease (2012). https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-Anemia-Guideline-English.pdf. Accessed December 11, 2023.</div>
</li>
<li>
<div class="reference">
                  Triferic (ferric pyrophosphate citrate) [prescribing information]. Wixom, MI: Rockwell Medical Inc; April 2018.</div>
</li>
<li>
<div class="reference">
                  Triferic AVNU (ferric pyrophosphate citrate) [prescribing information]. Wixom, MI: Rockwell Medical Inc; March 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and Mineral Nutrition Information System. https://iris.who.int/bitstream/handle/10665/85839/WHO_NMH_NHD_MNM_11.1_eng.pdf?sequence=22. Published 2011. Accessed December 11, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.2">
<a name="WHO.2"></a>World Health Organization (WHO). Serum ferritin concentrations for the assessment of iron status in individuals and populations: technical brief. https://iris.who.int/bitstream/handle/10665/337666/9789240008526-eng.pdf?sequence=1. Published 2020. Accessed December 11, 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 99572 Version 97.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
